Expressions of Interest

 

RE: Comparative Evaluation of Commercially Available SARS-CoV-2 Antibody Tests

 

The World Health Organization (WHO) is exploring the interest of companies to participate in a large comparative evaluation of commercially available antibody detecting tests for SARS-CoV-2 at NRL and in cooperation of other partners including FIND, Erasmus Medical Centre, Duke NUS Singapore and the International Vaccines Institute.

 

The WHO SARS-CoV-2 antibody detecting assay performance evaluation will commence in December, 2020 under the coordination of WHO/WHE (World Health Emergencies programme). Tests of different formats e.g. ELISA, RDT, that are commercially available to detect antibodies against SARS-CoV-2 will be eligible.

 

Participation in the evaluation scheme requires acceptance to enter the WHO Emergency Use Listing process 

(pre-submission call and letter of  application).  

 

The EOI should be completed by 7 December 2020 using the online web-form found here: https://extranet.who.int/dataformv3/index.php/182642?lang=en 

If any problems are encountered with this contact method, please send an email to WHElab@who.int with the subject heading: SARS-CoV-2 antibody assay comparative performance evaluation: EOI

Contact Us

 Address: 4th Floor, Healy BuildinNRL

4th Floor, Healy Building

41 Victoria Parade

Fitzroy VIC 3065

Australia

Fax: +61 3 9418 1155

Phone: +61 3 9418 1111

Email: info@nrlquality.org.au

Social Media

  • Twitter Social Icon
  • LinkedIn Social Icon

NRL is designated a WHO Collaborating Centre for Diagnostics and Laboratory Support for HIV and AIDS and Other Blood-borne Infections